- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04779125
APEMESH II - Perineal Reconstruction
January 31, 2024 updated by: Elisa Mäkäräinen, University of Oulu
Apemesh II - Perineal Reconstruction With Mesh Enhanced Gluteus Plasty
The objective of this pilot study is to assess the safety, functional outcome, feasibility and the potential benefits of synthetic mesh strip and gluteus flap reconstruction in perineum in case-control setting.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Several studies have reported over 30% morbidity with perineal wound healing after abdominoperineal resection.
Preoperative radiotherapy seems to be a strong predictor for perineal complications.
Musculocutaneus flaps and use of biological mesh seem to minimize perineal morbidity.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Elisa Mäkäräinen-Uhlbäck, M.D.
- Phone Number: +35883152282
- Email: elisa.makarainen-uhlback@ppshp.fi
Study Contact Backup
- Name: Katariina Kilpivaara, M.D.
- Phone Number: +35883152011
- Email: katariina.kilpivaara@ppshp.fi
Study Locations
-
-
-
Oulu, Finland
- Oulu University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Curative intent abdominoperineal resection and permanent colostomy
Exclusion Criteria:
- Patient with a comorbid illness or condition that would preclude the use of surgery (ASA 4- 5)
- Immunosupression (cortisone >10mg/day) or severe malnutrition (BMI <20)
- Diabetes with 1 or more organ damage
- Dialysis treatment
- Hepatic cirrhosis Child-Bugh B-C
- Potentially curable resection not possible
- Patient undergoing emergency procedures
- Metastatic disease
- Vaginal resection, pelvic exenteration and sacrum resection
- Vaginal perforation
- Pelvic abscess or perforated tumor
- Pregnant or suspected pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gluteus plasty enhanced with Progrip self gripping mesh
All study patietns will have a gluteus enhanced plasty after abdominoperineal reconstruction.
|
Intervention group will be compared to historical patients in a case-control setting.
Intervention group will have a mesh enhanced gluteus plasty made to reconstruct perineum after abdominoperineal resection.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complications
Time Frame: 30 days
|
Comprehensive complication index
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgical site infections
Time Frame: 30 days
|
Surgical site infections
|
30 days
|
Reoperation rate
Time Frame: 30 days
|
Reoperation rate
|
30 days
|
Operative time
Time Frame: 30 days
|
Operative time to reconstruct perineum
|
30 days
|
Length of hospital stay
Time Frame: 30 days
|
Primary length of stay at the hospital
|
30 days
|
Costs of treatment materials
Time Frame: 30 days
|
Costs of treatment materials
|
30 days
|
Total perineal healing time
Time Frame: 1 year
|
Time from operation to complete perineal healing
|
1 year
|
Perineal fistula
Time Frame: 30 days
|
Perineal sinus or fistula
|
30 days
|
Perineal hernia
Time Frame: 12 months
|
Perineal hernia incidence
|
12 months
|
Gluteus muscle function measured by time stands test
Time Frame: 12 months
|
Gluteus muscle function measured by time stands test
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Chair: Tero Rautio, M.D. Ph.D., Oulu University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 19, 2021
Primary Completion (Actual)
March 1, 2022
Study Completion (Actual)
March 1, 2022
Study Registration Dates
First Submitted
February 22, 2021
First Submitted That Met QC Criteria
March 2, 2021
First Posted (Actual)
March 3, 2021
Study Record Updates
Last Update Posted (Estimated)
February 1, 2024
Last Update Submitted That Met QC Criteria
January 31, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 115/2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
-
National Cancer Institute (NCI)Active, not recruitingMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
Clinical Trials on Gluteus plasty enhanced with Progrip self gripping mesh
-
Fundacion para la Investigacion Biomedica del Hospital...MedtronicRecruitingPostoperative Complications | Kidney Transplantation | Incisional HerniaSpain
-
Mahidol UniversityRamathibodi HospitalRecruitingLaparoscopic Inguinal Hernia RepairThailand